GleamWall
中文EN

GYRE GYRE THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1124105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.4%
TTM net income YoY-801.1%
TTM EPS YoY-2,500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin94.1%
Operating margin-20.6%
Net margin-30.1%
FCF margin-20.3%
EBITDA margin-18.8%

Returns

ROE-34.9%
ROA-20.3%
ROIC (approx.)-31.0%
Asset turnover0.68x

Leverage & solvency

Liabilities / assets17.5%
Debt / equity0.00x
Current ratio4.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$116.59M$105.76M
Cost of revenue$5.42M$3.88M
Gross profit$111.17M$101.87M
R&D expense$13.70M$12.02M
SG&A expense$20.80M$16.11M
Operating income$11.49M$16.16M
Pretax income$14.44M$23.22M
Income tax$4.56M$5.32M
Net income$9.88M$17.90M
EBITDA$13.97M$17.71M
EPS (basic)0.060.14
EPS (diluted)0.020.05
Weighted avg. shares (diluted)103.18M102.29M
Banking
Net interest income$1.75M$1.55M
Balance sheet
Cash & equivalents$49.19M$11.81M
Short-term investments$15.36M$14.86M
Receivables$31.08M$19.59M
Inventory$10.17M$6.34M
Current assets$149.36M$64.79M
PP&E, net$27.55M$23.88M
Intangibles$4.73M$273,000
Total assets$219.76M$125.41M
Current liabilities$23.78M$19.52M
Total liabilities$31.40M$27.00M
Shareholders' equity$62.50M$63.32M
Shares outstanding91.31M86.31M
Cash flow statement
Operating cash flow$1.01M-$3.64M
Capital expenditure$1.19M$2.31M
Free cash flow-$180,000-$5.96M
Investing cash flow-$474,000-$19.88M
Financing cash flow$24.38M$2.10M
Depreciation & amortization$2.48M$1.55M
Stock-based compensation$7.16M$831,000

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.